SG11201507521UA - Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) - Google Patents

Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)

Info

Publication number
SG11201507521UA
SG11201507521UA SG11201507521UA SG11201507521UA SG11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA SG 11201507521U A SG11201507521U A SG 11201507521UA
Authority
SG
Singapore
Prior art keywords
mesenschymal
msc
therapy
determining
stromal cells
Prior art date
Application number
SG11201507521UA
Other languages
English (en)
Inventor
La Rosa Olga De
Eleuterio Lombardo
Wilfried Dalemans
Original Assignee
Tigenix S A U
Tigenix Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U, Tigenix Nv filed Critical Tigenix S A U
Publication of SG11201507521UA publication Critical patent/SG11201507521UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70517—CD8
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
SG11201507521UA 2013-03-15 2014-03-17 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc) SG11201507521UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382091 2013-03-15
PCT/EP2014/055282 WO2014140362A2 (fr) 2013-03-15 2014-03-17 Biomarqueurs lymphocytaires destinés à déterminer la réponse clinique à une thérapie cellulaire

Publications (1)

Publication Number Publication Date
SG11201507521UA true SG11201507521UA (en) 2015-10-29

Family

ID=48044710

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507521UA SG11201507521UA (en) 2013-03-15 2014-03-17 Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)

Country Status (14)

Country Link
US (2) US10660920B2 (fr)
EP (2) EP3581932A1 (fr)
JP (2) JP6567430B2 (fr)
AU (2) AU2014230014B2 (fr)
CA (2) CA3188652A1 (fr)
DK (1) DK2972368T3 (fr)
ES (1) ES2748825T3 (fr)
HK (1) HK1219775A1 (fr)
HU (1) HUE046531T2 (fr)
IL (1) IL241586B (fr)
PL (1) PL2972368T3 (fr)
PT (1) PT2972368T (fr)
SG (1) SG11201507521UA (fr)
WO (1) WO2014140362A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
EP3581932A1 (fr) 2013-03-15 2019-12-18 TiGenix, S.A.U. Biomarqueurs lymphocytaires destinés à déterminer la réponse clinique à une thérapie cellulaire
CA2983950A1 (fr) * 2015-04-24 2016-10-27 Tigenix S.A.U. Biomarqueurs de determination de la reponse clinique a une therapie cellulaire
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN110691600B (zh) * 2016-11-11 2024-04-16 美商生命科学有限公司 使用人类间充质干细胞以实现细胞免疫及体液免疫的方法
BR112021016316A8 (pt) * 2019-02-27 2023-04-11 Tigenix S A U Método in vitro para selecionar uma população de células-tronco (sc), composição farmacêutica, método para preparar uma composição farmacêutica, uso da composição farmacêutica e uso da população de sc
WO2021207192A1 (fr) * 2020-04-08 2021-10-14 Figene, Llc Procédés et compositions pour le traitement d'allergies et d'asthme à l'aide de fibroblastes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043511D1 (de) * 1999-10-20 2010-01-21 Chugai Pharmaceutical Co Ltd Verwendung von g-csf zur hemmung der gvhd
EP2824174B1 (fr) * 2004-03-22 2018-11-28 Mesoblast International Sàrl Cellules souches mésenchymateuses et utilisations associées
EP1871419A4 (fr) * 2005-04-22 2009-01-14 Univ Maryland Methodes de traitement du rejet d'une greffe contre l'hote
EP2694080B1 (fr) * 2011-04-06 2018-03-14 SanBio, Inc. Procédés et compositions destinés à moduler la fonction immunitaire périphérique
EP3581932A1 (fr) 2013-03-15 2019-12-18 TiGenix, S.A.U. Biomarqueurs lymphocytaires destinés à déterminer la réponse clinique à une thérapie cellulaire

Also Published As

Publication number Publication date
WO2014140362A2 (fr) 2014-09-18
JP2019215359A (ja) 2019-12-19
WO2014140362A3 (fr) 2015-04-16
US11478511B2 (en) 2022-10-25
HK1219775A1 (zh) 2017-04-13
HUE046531T2 (hu) 2020-03-30
EP2972368B1 (fr) 2019-07-24
EP2972368A2 (fr) 2016-01-20
US20200261511A1 (en) 2020-08-20
JP2016516985A (ja) 2016-06-09
CA2906299C (fr) 2023-04-04
CA2906299A1 (fr) 2014-09-18
AU2020200807B2 (en) 2021-10-28
US20160067285A1 (en) 2016-03-10
DK2972368T3 (da) 2019-10-07
JP6567430B2 (ja) 2019-08-28
ES2748825T3 (es) 2020-03-18
US10660920B2 (en) 2020-05-26
JP6883070B2 (ja) 2021-06-09
PT2972368T (pt) 2019-10-18
IL241586B (en) 2019-02-28
AU2014230014A1 (en) 2015-10-29
EP3581932A1 (fr) 2019-12-18
CA3188652A1 (fr) 2014-09-18
PL2972368T3 (pl) 2020-03-31
AU2020200807A1 (en) 2020-02-20
AU2014230014B2 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
EP3010570A4 (fr) Interface clinique
IL241586B (en) Lymphocyte biomarkers for determining clinical response to mesenchymal stromal cell therapy
EP2872533A4 (fr) Procédés d'évaluation de l'aptitude de lymphocytes t transduits à être administrés
EP2871470A4 (fr) Biocapteur électrochimique avec précision améliorée
HK1221250A1 (zh) 用於培養細胞的結構件
PL2784454T3 (pl) Diagnostyka ogniwa obciążnikowego
HK1213830A1 (zh) 用於預測醋酸格拉替雷臨床反應的生物標誌物
EP3058347A4 (fr) Cellule de mesure photométrique
EP2975110A4 (fr) Dispositif de culture cellulaire
IL245265B (en) Antibodies specific for fcrn
HUP1200239A2 (en) Quantitative biomarkers of the erythrocyte membrane
GB2518263B (en) Diamond based electrochemical sensors
HK1202621A1 (en) Analyte meter for test strips
DK2951552T3 (da) Opfangningsanordning til engangsbrug
EP3052943A4 (fr) Biomarqueurs pour thérapie cellulaire
HK1250176A1 (zh) 用於確定細胞療法的臨床反應的生物標誌物
GB2517918B (en) Weighing scale system with interface component
GB201316131D0 (en) Biomarkers for disease stratification
GB201315532D0 (en) Methods for detecting proteins
HK1216265A1 (zh) 抗- 抗體的細胞遷移測定方法
EP3060917A4 (fr) Dosages pour analytes macromoléculaires
EP2957907A4 (fr) PROCÉDÉ DE DÉTECTION D'UNE CELLULE À GÈNE c-MET AMPLIFIÉ
HUP1300692A2 (en) Honeycomb connection for hives with improved features
GB201300887D0 (en) Biodiesel Processor
SG11201508791WA (en) Melt curve analysis